retatrutide peptide legal Side Effects: What Patients Should Know Since January 2026, there have

Studies find that diets based on certain types of food, such as highly processed foods or foods high in fat and sugars, dysregulate food intake, leading to obesity (Hedrih, 2023)

Although direct clinical evidence of systemic NAD(P) depletion during GLP-1RA therapy is lacking, experimental and observational studies suggest that NAD turnover and micronutrient status can be altered in obesity and inflammatory states [83, 85], supporting the biological plausibility of substrate-sensitive vulnerability

However, no completed trial has examined the effect of GLP-1 RAs on cardiovascular events in patients with established CVD and overweight/obesity in the absence of type 2 diabetes

Embrace the journey, stay consistent, and celebrate every milestone along the way